26-01-2017 дата публикации
Номер: US20170020821A1
Принадлежит:
Disclosed are pharmaceutical compositions comprising a compound having the formula: 139-. (canceled)41. The method of claim 40 , wherein the methanesulfonic acid or an anion thereof claim 40 , and the compound of Formula I or a cation thereof claim 40 , are present in the feed solution in a molar ratio of the methanesulfonic acid or an anion thereof claim 40 , to the compound of Formula I or a cation thereof claim 40 , of between 2:1 and 3:1.42. The method of claim 40 , wherein the mesylate salt of the compound of Formula I is a bis-mesylate salt of the compound of Formula I claim 40 , or a hydrate thereof.43. The method of claim 40 , wherein the mesylate salt is a monohydrate claim 40 , bis-mesylate salt of the compound of Formula I.4550-. (canceled)52. The method of claim 51 , wherein the condition is selected from the group consisting of acute lymphocytic leukemia (ALL) claim 51 , acute myeloid leukemia (AML) claim 51 , chronic lymphocytic leukemia (CLL) claim 51 , small lymphocytic lymphoma (SLL) claim 51 , myelodysplastic syndrome (MDS) claim 51 , myeloproliferative disease (MPD) claim 51 , chronic myeloid leukemia (CML) claim 51 , multiple myeloma (MM) claim 51 , non-Hodgkin's lymphoma (NHL) claim 51 , mantle cell lymphoma (MCL) claim 51 , follicular lymphoma (FL) claim 51 , Waldestrom's macroglobulinemia (WM) claim 51 , T-cell lymphoma claim 51 , B-cell lymphoma claim 51 , diffuse large B-cell lymphoma (DLBCL) claim 51 , lymphoplasmacytic lymphoma (LPL) claim 51 , and marginal zone lymphoma (MZL).53. The method of claim 52 , wherein the condition is non-Hodgkin's lymphoma (NHL).54. The method of claim 53 , wherein the NHL is indolent non-Hodgkin's lymphoma (iNHL).55. The method of claim 54 , wherein the iNHL is refractory iNHL.56. The method of claim 54 , wherein the iNHL is non-FL iNHL.57. The method of claim 51 , wherein the condition is selected from the group consisting of asthma claim 51 , rheumatoid arthritis claim 51 , multiple sclerosis claim 51 , and ...
Подробнее